Tabea Wilhelm

TL;DR: Dabrafenib has activity and an acceptable safety profile in patients with Val600Glu BRAF-mutant melanoma and brain metastases irrespective of whether they are untreated or have been previously treated but have progressed.

TL;DR: In this article, a wide spectrum of Ipilimumab-induced adverse events including drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis were documented.

TL;DR: Dabrafenib was well tolerated and clinically active in patients with BRAF(V600E/K) mut(+) MM and cfDNA may be a useful prognostic and response marker in future studies.

TL;DR: This case highlights cerebellar ataxia in the absence of seizures as a clinical manifestation of GABAB receptor autoimmunity and extends the spectrum of tumors underlying this condition to malignant melanoma.

TL;DR: In this article, the authors explored the impact of selective BRAF inhibitors on the hosts' immune system using flow cytometry and multiplex assays, and found that vemurafenib but not dabrafenib decreases patients peripheral lymphocyte counts and alters CD4 + T cell phenotype and function.